UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Buys 6,494 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in Vera Therapeutics, Inc. (NASDAQ:VERA) by 11.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 61,574 shares of the company’s stock after acquiring an additional 6,494 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Vera Therapeutics were worth $2,722,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Samlyn Capital LLC grew its position in Vera Therapeutics by 90.8% in the 2nd quarter. Samlyn Capital LLC now owns 1,231,911 shares of the company’s stock worth $44,571,000 after purchasing an additional 586,410 shares in the last quarter. First Light Asset Management LLC lifted its position in shares of Vera Therapeutics by 130.6% during the 2nd quarter. First Light Asset Management LLC now owns 1,005,723 shares of the company’s stock worth $36,387,000 after buying an additional 569,590 shares in the last quarter. American Century Companies Inc. purchased a new position in shares of Vera Therapeutics in the 2nd quarter worth approximately $14,015,000. Logos Global Management LP grew its holdings in shares of Vera Therapeutics by 65.2% in the second quarter. Logos Global Management LP now owns 950,000 shares of the company’s stock valued at $34,371,000 after acquiring an additional 375,000 shares in the last quarter. Finally, Federated Hermes Inc. purchased a new stake in shares of Vera Therapeutics during the second quarter valued at approximately $10,492,000. Hedge funds and other institutional investors own 99.21% of the company’s stock.

Analyst Ratings Changes

Several research firms have weighed in on VERA. JPMorgan Chase & Co. boosted their price objective on Vera Therapeutics from $72.00 to $75.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 5th. Wedbush boosted their price target on shares of Vera Therapeutics from $30.00 to $38.00 and gave the stock a “neutral” rating in a report on Friday, November 8th. Evercore ISI upgraded shares of Vera Therapeutics to a “strong-buy” rating in a research report on Monday, September 16th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $107.00 price objective on shares of Vera Therapeutics in a research report on Tuesday, October 1st. Finally, Scotiabank assumed coverage on shares of Vera Therapeutics in a research report on Wednesday, October 16th. They set a “sector outperform” rating and a $60.00 target price for the company. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $59.22.

Insiders Place Their Bets

In related news, CEO Marshall Fordyce sold 17,500 shares of the business’s stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $46.94, for a total transaction of $821,450.00. Following the sale, the chief executive officer now directly owns 85,942 shares in the company, valued at approximately $4,034,117.48. The trade was a 16.92 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Beth C. Seidenberg sold 15,000 shares of the firm’s stock in a transaction dated Monday, October 28th. The stock was sold at an average price of $48.03, for a total value of $720,450.00. Following the completion of the transaction, the director now owns 131,553 shares of the company’s stock, valued at approximately $6,318,490.59. This represents a 10.24 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 91,802 shares of company stock worth $4,036,308 over the last 90 days. Corporate insiders own 21.70% of the company’s stock.

Vera Therapeutics Price Performance

NASDAQ VERA opened at $44.05 on Friday. The company has a market cap of $2.79 billion, a PE ratio of -16.88 and a beta of 1.08. The company has a quick ratio of 13.76, a current ratio of 13.76 and a debt-to-equity ratio of 0.17. The firm’s 50-day simple moving average is $45.00 and its two-hundred day simple moving average is $40.34. Vera Therapeutics, Inc. has a 52 week low of $14.08 and a 52 week high of $51.61.

Vera Therapeutics (NASDAQ:VERA) last released its quarterly earnings data on Thursday, November 7th. The company reported ($0.85) EPS for the quarter, missing the consensus estimate of ($0.64) by ($0.21). Research analysts predict that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current year.

Vera Therapeutics Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.